Literature DB >> 19696211

Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients.

Graham Peter Mead, Mark Trehane Drayson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19696211      PMCID： PMC2731646          DOI： 10.1182/blood-2009-06-225854

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Demonstration of changes in plasma cell subsets in multiple myeloma.

Authors:  Michael John Ayliffe; Faith Elizabeth Davies; David de Castro; Gareth John Morgan
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

2.  The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.

Authors:  Seema Singhal; Eric Vickrey; Jairam Krishnamurthy; Veerpal Singh; Sharon Allen; Jayesh Mehta
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

3.  Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Authors:  M Drayson; L X Tang; R Drew; G P Mead; H Carr-Smith; A R Bradwell
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

5.  Serum test for assessment of patients with Bence Jones myeloma.

Authors:  Arthur R Bradwell; Hugh D Carr-Smith; Graham P Mead; Timothy C Harvey; Mark T Drayson
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

6.  Serum free light chains for monitoring multiple myeloma.

Authors:  G P Mead; H D Carr-Smith; M T Drayson; G J Morgan; J A Child; A R Bradwell
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

7.  Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.

Authors:  C L H Snozek; J A Katzmann; R A Kyle; A Dispenzieri; D R Larson; T M Therneau; L J Melton; S Kumar; P R Greipp; R J Clark; S V Rajkumar
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528
  7 in total
  4 in total

Review 1.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.

Authors:  Jie Chen; Meng Fang; Yun-Peng Zhao; Chang-Hong Yi; Jun Ji; Cheng Cheng; Meng-Meng Wang; Xing Gu; Quan-Sheng Sun; Xiao-Ling Chen; Chun-Fang Gao
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

Review 3.  Deep Response in Multiple Myeloma: A Critical Review.

Authors:  Mariateresa Fulciniti; Nikhil C Munshi; Joaquin Martinez-Lopez
Journal:  Biomed Res Int       Date:  2015-12-10       Impact factor: 3.411

4.  Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Authors:  Stefania Oliva; Manuela Gambella; Milena Gilestro; Vittorio Emanuele Muccio; Francesca Gay; Daniela Drandi; Simone Ferrero; Roberto Passera; Chiara Pautasso; Annalisa Bernardini; Mariella Genuardi; Francesca Patriarca; Elona Saraci; Maria Teresa Petrucci; Norbert Pescosta; Anna Marina Liberati; Tommaso Caravita; Concetta Conticello; Alberto Rocci; Pellegrino Musto; Mario Boccadoro; Antonio Palumbo; Paola Omedè
Journal:  Oncotarget       Date:  2017-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.